Open AccessCefixime-associated acute generalized exanthematous pustulosis: Rare cases in India
Author(s) -
Vipin Kumar,
Vivekanandan Kalaiselvan,
A Pramod Kumar,
Archana Saurabh,
Prasad Thota,
Shabir Sidhu,
Bikash Medhi
Publication year - 2018
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/ijp.ijp_673_17
Subject(s) - acute generalized exanthematous pustulosis , cefixime , medicine , dermatology , ceftriaxone , biology , antibiotics , microbiology and biotechnology
Cefixime is a widely used third-generation cephalosporin schedule H1 drug, which is prescribed for the treatment of otitis media, respiratory tract infections, and uncomplicated urinary tract infections and is effective against infections caused by Enterobacteriaceae and Haemophilus influenzae species in India. The National Coordination Centre (NCC)-Pharmacovigilance Programme of India (PvPI), Indian Pharmacopoeia Commission (IPC), has received rare individual case safety reports (ICSRs) for acute generalized exanthematous pustulosis (AGEP) associated with the use of cefixime.